MedTrace Logo

AbATE Follow-Up Study

NCT02067923 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 44

Last updated 2018-01-17

No results posted yet for this study

Summary

This study proposes to conduct a non-interventional, multi-center trial that will look at C-peptide results from one or two Mixed Meal Tolerance Tests (MMTT) in participants who received anti-CD3 treatment or placebo on the Abate ITN027AI trial. Anti-CD3 monoclonal antibody is a humanized antibody that is commonly used to prevent organ rejection. It was give in order to determine whether anti-CD3 mAb treatment can halt the progression of newly diagnosed type 1 diabetes.

The overall hypothesis of this study is there will be less change in c-peptide levels of the previously treated group versus the control group.

Conditions

  • Diabetes Mellitus, Type 1

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Kevan Herold, MD · Yale University

Eligibility

Min Age
10 Years
Max Age
37 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2016-01-31
Completion
2016-11-17

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02067923 on ClinicalTrials.gov